The trial is designed to identify an appropriate dose of QAB149 for delivery via a multiple dose inhaler for use in the COPD Phase III program.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
686
Pulmonary function measured between 22 and 24 hours after dosing on Day 1
Pulmonary function measured on days 1 and 7 at various intervals after dosing
Safety measurements
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
UAB Pulmonary Research
Birmingham, Alabama, United States
Diagnostic & Medical Clinic
Mobile, Alabama, United States
The University of South Alabama Medical Center
Mobile, Alabama, United States
Pulmonary Associates
Phoenix, Arizona, United States
USC Rancho Amigos Medical Center
Downey, California, United States
Radiant Research
Encinitas, California, United States
Allergy Research Foundation , Inc
Los Angeles, California, United States
David Geffin UCLA School of Medicine
Los Angeles, California, United States
Southern California Research
Mission Viejo, California, United States
California Allergy & Asthma Medical Group
Palmdale, California, United States
...and 44 more locations